-+ 0.00%
-+ 0.00%
-+ 0.00%

Faeth Therapeutics Presents Phase 2 Data Showing 33% Response Rate With PIKTOR Plus Paclitaxel in Efficacy-Evaluable Endometrial Cancer Patients

PUBT·11/09/2026 14:06:13
Listen to the news
Faeth Therapeutics Presents Phase 2 Data Showing 33% Response Rate With PIKTOR Plus Paclitaxel in Efficacy-Evaluable Endometrial Cancer Patients
  • Faeth Therapeutics reported a 33% confirmed response rate with PIKTOR and paclitaxel in 36 efficacy-evaluable endometrial cancer patients in Phase 2.
  • Preliminary median progression-free survival reached 7.4 months across all 42 treated patients; six-month progression-free survival was 62%.
  • Two patients discontinued because of treatment-related adverse events; no drug-related deaths occurred.
  • Funding is expected to cover mature Phase 2 data disclosure and interim Phase 1b/2 breast cancer data expected in second-half 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Faeth Therapeutics Inc published the original content used to generate this news brief on November 09, 2026, and is solely responsible for the information contained therein.